Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PETReA in previously untreated high-tumor-burden follicular lymphoma
2016-004010-10Phase 3Unknown
- Sponsor
- University of Liverpool
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab, lenalidomide and obinutuzumab in follicular lymphoma (FL) and mature B-cell lymphoma (4 arms), sponsored by University of Liverpool. Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
rituximablenalidomideobinutuzumab
03
Conditions
follicular lymphoma (FL)mature B-cell lymphoma
Beyond the preview
Go deeper on 2016-004010-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004010-10.